Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours Β· Estimated delivery Aug 23 - Aug 28
For professional use only
The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task
A Sanofi spokesperson told BioSpace in an emailed statement that the company made the strategic decision of focusing on offering the combination therapy Soliqua consisting of GLP-1 and basal insulin to help people manage their diabetes. The spokesperson added that Soliqua has since become one of the cornerstone therapies in its diabetes portfolio and represents an important growth asset for the company
"In this field, we like to talk about really individualizing treatment for a single patient, so there's going to be some patients that may really want this option."
US$ 25.52
US$ 29.33
US$ 23.19
US$ 27.04
US$ 29.94
